Nanobiotix
June 17, 2025
Company Presentation
Platform for Therapeutics
154
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States). Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) NBTXR3 (radioenhancer); 2) Curadigm (bioavailability and biodistribution) and 3) Oocuity (disorders of the central nervous system).
Company HQ City:
Paris
Company HQ State:
Ile de France
Company HQ Country:
France
Year Founded:
2004
Lead Product in Development:
NBTXR3
CEO
Laurent Levy
Development Phase of Lead Product
Phase III
Exchange
Euronext Paris / Nasdaq
Ticker
Nanobiotix/ NBTX
When you expect your next catalyst update?
Phase III in HNSCC: interim readout
What is your next catalyst (value inflection) update?
last patient in expected H1 2026.
Website
www.nanobiotix.com²
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}